Table 2 Patient demographics.
Characteristics, n (%) | IV ceftriaxone (n = 69) | Oral ciprofloxacin (n = 70) | All subjects (n = 139) |
|---|---|---|---|
Age | |||
Mean (SD) | 56.4 (13.0) | 60.1 (14.5) | 58.3 (13.8) |
Median (Q1–Q3) | 58 (44–72) | 62 (45–79) | 58 (42–74) |
Gender (n, %) | |||
Male | 53 (76.8) | 52 (74.3) | 105 (75.5) |
Female | 16 (23.2) | 18(25.7) | 34 (24.5) |
Ethnicity (n, %) | |||
Chinese | 52 (75.4) | 58 (82.9) | 110 (79.1) |
Indian | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Malay | 16 (23.2) | 10(14.3) | 26 (18.7) |
Other | 1 (1.4) | 2 (2.9) | 3 (2.2) |
Medical condition (n, %) | |||
Diabetes mellitus | 38 (55.1) | 30 (42.9) | 68 (48.9) |
Cardiovascular disease | 27 (39.1) | 26 (37.1) | 53 (38.1) |
Pulmonary disease | 4 (5.8) | 6 (8.6) | 10 (7.2) |
Hepatic disease | 4 (5.8) | 5 (7.1) | 9 (6.5) |
Biliary tract disease | 8 (11.6) | 4 (5.7) | 12 (8.6) |
Gastrointestinal tract disease | 5 (7.3) | 7 (10.0) | 12 (8.6) |
Chronic kidney disease | 1 (1.5) | 3 (4.3) | 4 (2.9) |
Malignancy | 2 (2.9) | 4 (5.7) | 6 (4.3) |
Neurologic disease | 5 (7.3) | 3 (4.3) | 8 (5.8) |
Rheumatologic/autoimmune disease | 2 (2.9) | 0 (0.0) | 2 (1.4) |
Others | 45 (65.2) | 44 (62.9) | 89 (64.0) |
Antibiotics | |||
Number of antibiotics since admission (mean, SD) | 2.8 (1.2) | 2.9 (1.1) | 2.8 (1.1) |
Number of antibiotics since admission (median, Q1–Q3) | 3.0 (1.0–5.0) | 3.0 (1.0–5.0) | 3.0 (1.0–5.0) |
Patients with effective antibiotic use (n, %) | 70 (100.0) | 69 (100.0) | 139 (100.0) |
Days of effective antibiotics, Median (Q1–Q3) | 5.0 (3.0–7.0) | 5.0 (4.0–6.0) | 5.0 (3.0–7.0) |
